Patents by Inventor Philippe Goyette

Philippe Goyette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MALLEABLE PROTEIN MATRIX AND USES THEREOF
    Publication number: 20140328878
    Abstract: The present invention relates to a malleable protein matrix (MPM), which is the reaction product of the agglomeration of proteins after a fermentation process and is exhibiting biological activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophylic substances. The present invention also relates to the process for the preparation of the malleable protein matrix and its usages.
    Type: Application
    Filed: January 8, 2014
    Publication date: November 6, 2014
    Applicant: Technologies Biolactis Inc.
    Inventors: Eric Simard, Dominique Pilote, Claude DuPont, Nathalie Lajoie, Marcel Paquet, Pierre Lemieux, Philippe Goyette
  • Exopolysaccharides delivery system for active molecules
    Patent number: 8088605
    Abstract: The present invention relates to a delivery system for delivery of an active molecule to a patient, the delivery system comprising a population of exopolysaccharide micelles, each micelle defining a core for containing the active molecule.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: January 3, 2012
    Assignees: Technologies Biolactics Inc., INRS (Institute National de Recherche Scientifique)
    Inventors: Nicolas Beaudet, Claude Dupont, Pierre Lemieux, Eric Simard, Philippe Goyette
  • CHEMOTHERAPEUTIC AGENTS AS ANTI-CANCER VACCINE ADJUVANTS AND THERAPEUTIC METHODS THEREOF
    Publication number: 20100272676
    Abstract: The present invention relates to an anti-cancer vaccine composition comprising an antigen in association with an effective amount of at least one immunomodulator chemotherapeutic adjuvant eliciting an immune response in a patient and a pharmaceutically acceptable carrier. It also relates to method of preventing tumor growth and reducing tumor growth using the anti-cancer vaccine composition of the present invention.
    Type: Application
    Filed: April 2, 2010
    Publication date: October 28, 2010
    Applicant: TECHNOLOGIES BIOLACTIS INC.
    Inventors: Éric Simard, Philippe Goyette, Pierre Lemieux
  • Malleable protein matrix and uses thereof
    Publication number: 20060057131
    Abstract: The present invention relates to a malleable protein matrice (MPM), which is the reaction product of the agglomeration of proteins after a fermentation process and is exhibiting biological activities and is suitable for the incorporation (or encapsulation) of various hydrophilic or lipophylic substances. The present invention also relates to the process for the preparation of the malleable protein matrice and its usages.
    Type: Application
    Filed: December 20, 2002
    Publication date: March 16, 2006
    Inventors: Eric Simard, Dominique Pilote, Claude DuPont, Nathalie Lajoie, Marcel Paquet, Pierre Lemieux, Philippe Goyette
  • Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
    Publication number: 20060051354
    Abstract: The present invention relates to an anti-cancer vaccine composition comprising an antigen in association with an effective amount of at least one immunomodulator chemotherapeutic adjuvant eliciting an immune response in a patient and a pharmaceutically acceptable carrier. It also relates to method of preventing tumor growth and reducing tumor growth using the anti-cancer vaccine composition of the present invention.
    Type: Application
    Filed: March 25, 2003
    Publication date: March 9, 2006
    Inventors: Eric Simard, Philippe Goyette, Pierre Lemieux
  • Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
    Publication number: 20040073018
    Abstract: The invention features a method for detecting an increased likelihood of hyperhomocysteinemia and, in turn, an increased or decreased likelihood of neural tube defects or cardiovascular disease. The invention also features therapeutic methods for reducing the risk of neural tube defects, colon cancers and related cancers. Also provided are the sequences of the human methionine synthase gene and protein and compounds and kits for performing the methods of the invention.
    Type: Application
    Filed: June 27, 2003
    Publication date: April 15, 2004
    Inventors: Roy A. Gravel, Rima Rozen, Daniel LeClerc, Philippe Goyette, Eric Campeau
  • Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
    Patent number: 6703197
    Abstract: The invention features a method for detecting an increased likelihood of hyperhomocysteinemia and, in turn, an increased or decreased likelihood of neural tube defects or cardiovascular disease. The invention also features therapeutic methods for reducing the risk of neural tube defects, colon cancers and related cancers. Also provided are the sequences of the human methionine synthase gene and protein and compounds and kits for performing the methods of the invention.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: March 9, 2004
    Assignee: Martinex R&D, Inc.
    Inventors: Roy A. Gravel, Rima Rozen, Daniel LeClerc, Philippe Goyette, Eric Campeau
  • cDNA for human methylenetetrahydrofolate reductase
    Publication number: 20030157530
    Abstract: Provided herein is a heretofore unknown isolated nucleic acid molecule which encodes human methylenetetrahydrofolate reducatase, along with an amino acid sequence of methylenetetrahydrofolate reductase, and a cDNA probe for human methylenetetrahydrofolate reductase. Also provided are a molecule description of mutations in humans resulting in a phenotype having reduced levels of methylenetetrahydrofolate reductase, and methods of diagnosing methylenetetrahydrofolate reductase deficiency in a human.
    Type: Application
    Filed: December 11, 2002
    Publication date: August 21, 2003
    Inventors: Rima Rozen, Philippe Goyette
  • Methods for detecting human methylenetetrahydrofolate reductase allelic variants
    Patent number: 6528259
    Abstract: Provided herein is a heretofore unknown isolated nucleic acid molecule which encodes human methylenetetrahydrofolate reducatase, along with an amino acid sequence of methylenetetrahydrofolate reductase, and a cDNA probe for human methylenetetrahydrofolate reductase. Also provided are a molecule description of mutations in humans resulting in a phenotype having reduced levels of methylenetetrahydrofolate reductase, and methods of diagnosing methylenetetrahydrofolate reductase deficiency in a human.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: March 4, 2003
    Assignee: McGill University
    Inventors: Rima Rozen, Philippe Goyette
  • Methods for detecting human methylene tetrahydrofolate reductase allelic variants
    Patent number: 6218120
    Abstract: Provided herein is a heretofore unknown isolated nucleic acid molecule which encodes human methylenetetrahydrofolate reducatase, along with an amino acid sequence of methylenetetrahydrofolate reductase, and a cDNA probe for human methylenetetrahydrofolate reductase. Also provided are a molecule description of mutations in humans resulting in a phenotype having reduced levels of methylenetetrahydrofolate reductase, and methods of diagnosing methylenetetrahydrofolate reductase deficiency in a human.
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: April 17, 2001
    Assignee: McGill University
    Inventors: Rima Rozen, Philippe Goyette
  • CDNA for human methylenetetrahydrofolate reductase
    Patent number: 6074821
    Abstract: The present invention relates to a cDNA probe for human methylenetetrahydrofolate reductase (MTHFR), and its uses. The probe of the present invention may be used for the identification of sequence abnormalities in patients with severe or mild MTHFR deficiency, including cardiovascular patients and patients with neurologic symptoms. A human MTHFR protein which hybridizes to the probe of the present invention may be used for therapy of MTHFR-deficiency patients by biochemical or pharmacological approaches.
    Type: Grant
    Filed: February 12, 1997
    Date of Patent: June 13, 2000
    Assignee: McGill University
    Inventors: Rima Rozen, Philippe Goyette